| Trial ID # | NCT02338622 |
| Phase | I |
| Drug Class | Signaling Pathway Inhibitors: PI3K-AKT-mTOR/AKT |
| Drug Name | Capivasertib |
| Alternate Drug Names | AZD5363, Akt inhibitor AZD5363 |
| Drugs in Trial | Olaparib, Capivasertib |
| Eligible Participant | Recurrent ovarian cancer |
| Patients Enrolled | 25 ovarian in dose escalation and dose expansion, median 5 prior therapies (1-12), 16 BRCA MUT |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Randomized |
| Endpoints | ORR, DCR, evaluated per RECIST |
| Efficacy | ORR: 24% (5PR, 1uPR - 3 Pt-S: 2BRCA MUT - 3 Pt-R: 2BRCA MUT, 1PTEN and KRAS and SMARCA4 MUT) |
| Conclusion | Capivasertib+olaparib is safe and tolerable and anti-tumor activity is observed in patients harboring tumors with BRCA MUT and BRCA WT cancers with or without somatic DDR and/or PI3K-AKT pathway alterations |
| Reference | Yap T et al. Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non-BRCA1/2-Mutant Cancers. Cancer Discov (2020) 10(10):1528-1543 |